OncRef

Clinical Trial: NCT03483012

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Dana-Farber Cancer Institute
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-04-21

Study Overview

Brief Summary

This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain.

The interventions involved in this study are:

  • Atezolizumab
  • Stereotactic radiosurgery (SRS)

Official Title

A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain Metastasis

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: Atezolizumab
  • Procedure: Stereotactic radiosurgery (SRS)

Other Study ID Numbers

  • 17-519

Start Date (Actual)

2018-05-01

Primary Completion Date (Actual)

2019-11-21

Study Completion Date (Actual)

2025-11-12

Enrollment (Actual)

6

Study Type

Interventional

Phase

Phase 2